<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Investigational therapies for management of heart failure</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Investigational therapies for management of heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Investigational therapies for management of heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of heart failure (HF) is designed to prolong survival, reduce morbidity, slow the progression of disease, and improve symptoms [<a href="#rid1">1</a>]. While conclusive trials established the efficacy of many HF therapies, other plausibly effective therapies remain investigational due to inconclusive evidence.</p><p>Investigational therapies for HF are reviewed here.</p><p>Standard therapies for HF are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p></p><p class="headingAnchor" id="H1715074956"><span class="h1">DEVICE-BASED THERAPIES</span></p><p class="headingAnchor" id="H4994533"><span class="h2">Parasympathetic stimulation</span><span class="headingEndMark"> — </span>In patients with HF, the decrease in parasympathetic nervous system (PNS) activity may contribute to the pathophysiology of HF [<a href="#rid2">2</a>], but it is unknown whether PNS stimulation is an effective treatment for HF. Based on animal models showing improvement in HF with PNS stimulation, the potential role of increasing PNS activity in the treatment of HF with reduced ejection fraction (HFrEF) is being evaluated in humans. Several trials are underway to examine the effects of increasing PNS activity via vagus nerve stimulation on cardiac structure, function, and clinical outcomes [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H647175840"><span class="h2">Enhanced external counterpulsation</span><span class="headingEndMark"> — </span>Enhanced external counterpulsation (EECP) is a technique that increases arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). EECP is applied by wrapping cuffs around the patient’s legs and applying sequential air pressure (300 mmHg) from the lower legs to the thighs in early diastole, which propels blood back to the heart.</p><p>In patients with HF, EECP is an unproven therapy; there are only limited data from subgroup analyses of trials and registries that show variable effects on exercise tolerance.</p><p>As an example, the PEECH trial directly evaluated the possible benefit of EECP in 187 patients with mild to moderate HF [<a href="#rid6">6</a>]. Patients were randomly assigned to standard medical therapy with seven to eight weeks of EECP or standard medical therapy alone. Patients assigned to EECP were slightly more likely to increase their total exercise time by more than 60 seconds (35 versus 25 percent with standard medical therapy). However, EECP did not have any effect on peak VO<sub>2</sub>. Thus, this study did not achieve positive results for one of its two primary end points. In addition, the results of this single-blind trial are subject to the placebo effect. Further research will be necessary to define the impact of EECP in the treatment of HF.</p><p>The use of EECP to treat angina is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1524.html" rel="external">"New therapies for angina pectoris", section on 'External counterpulsation'</a>.)</p><p class="headingAnchor" id="H3602588473"><span class="h2">Cardiac contractility modulation</span><span class="headingEndMark"> — </span>Cardiac contractility modulation (CCM) involves applying biphasic electric stimulation to the right ventricular septum during the cardiac absolute refractory period to induce a mild augmentation of left ventricular (LV) contraction that may lead to reverse LV remodeling and improve LV ejection fraction (LVEF) [<a href="#rid7">7</a>].</p><p>CCM may improve functional measures but has an unclear effect on long-term clinical outcomes and a relatively high risk of complications. However, the trials that tested the efficacy of CCM showed minimal or no effect of CCM on all-cause mortality, survival free of hospitalization, and changes in functional capacity. CCM was associated with a relatively high complication rate of approximately 10 percent. Accordingly, cardiac resynchronization therapy (CRT), which has more extensive supporting data, is the preferred approach in patients who qualify for CRT. (See  <a class="medical medical_review" href="/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system"</a>.)</p><p>Studies and trials of CCM include:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of three randomized controlled trials that included a total of 641 participants with HF found that CCM improved peak oxygen consumption (mean difference +0.7, 95% CI 0.2-1.2 mL/kg/min) and quality of life measured by Minnesota Living With Heart Failure Questionnaire (mean difference -7.2, 95% CI -10.4 to -4.0) but had an uncertain effect on six-minute walk test distance (mean difference +14 m, 95% CI -0.1 to 27.9 m) when compared with sham treatment or usual care [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent randomized trial (FIX-HF-5C) enrolled 160 patients with New York Heart Association (NYHA) functional class III or IV symptoms, QRS duration &lt;130 ms, and LVEF between 25 and 45 percent [<a href="#rid9">9</a>]. Survival free of cardiac death and HF hospitalization was significantly improved with CCM compared with usual care (97.1 versus 89.2 percent at 24 weeks). However, overall survival and survival free of any hospitalization were similar in the CCM and usual care groups. In the FIX-HF-5C cohort, six-minute walk test distance, quality of life measured by Minnesota Living With Heart Failure Questionnaire, and NYHA functional class improved in the group assigned to CCM. There was a 10.3 percent rate of device- or procedure-related complications with CCM.</p><p></p><p class="bulletIndent1">Combined data from FIX-HF-5C and FIX-HF-5 trials showed that peak oxygen consumption was significantly improved at 24 weeks with CCM compared with usual care (mean difference +0.84 mL/kg/min, 95% CI 0.12-1.55) [<a href="#rid9">9</a>].</p><p></p><p>While the benefits of CCM are unclear and possibly affected by the placebo effect, CCM is approved by the US Food and Drug Administration for use in patients with HFrEF who have NYHA functional class III or IV symptoms despite optimal medical therapy and who cannot undergo placement of a CRT device. There are ongoing trials and registries of CCM in patients with HF due to reduced or preserved ejection fraction [<a href="#rid10">10-15</a>].</p><p class="headingAnchor" id="H464299404"><span class="h1">STEM CELL THERAPY</span><span class="headingEndMark"> — </span>Cell therapy involves transfer of less-differentiated cells (eg, cardiac stem cells, skeletal myoblasts) to the myocardium to induce therapeutic myocardial regeneration and/or improvement in cardiac function. The benefit of cell therapy is uncertain in patients with HF [<a href="#rid16">16,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Theoretical basis</strong> – The most likely mechanism of benefit is a paracrine effect in which transplanted cells produce growth factors, cytokines, and other signaling molecules that may improve myocardial function via mechanisms such as increased myocardial perfusion due to angiogenesis or prolongation of the survival of myocytes or other cells [<a href="#rid18">18,19</a>]. It is unclear if cell therapies can incorporate into the myocardium and differentiate into functional myocardial tissue; some studies have demonstrated that hematopoietic stem cells do not transdifferentiate into cardiac myocytes [<a href="#rid20">20,21</a>], while autologous skeletal myoblasts can contract but do not transdifferentiate into cardiomyocytes [<a href="#rid18">18,22</a>]. Studies in animal models found that endogenous cardiac progenitor cells contribute minimal or no cardiomyocytes to the heart [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Clinical studies have investigated the efficacy of skeletal myoblasts, bone marrow mononuclear cells, bone marrow progenitor cells, mesenchymal stem cells, and cardiac stem cells to treat patients with chronic HF [<a href="#rid25">25</a>]. A systematic review and meta-analysis evaluated 38 randomized controlled trials that included 1907 participants with chronic ischemic heart disease and HF and that compared autologous adult stem/progenitor cells with no stem/progenitor cells [<a href="#rid26">26</a>]. The meta-analysis ultimately included nine trials with 491 participants and found low-quality evidence of mortality benefit at ≥12 months (risk ratio [RR] 0.42, 95% CI 0.21-0.87). Based on data from six trials with 375 participants, there was no significant reduction in the risk of hospitalization for HF (RR 0.63; 95% CI 0.36-1.09). Adverse events were infrequent, and no long-term adverse events were reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong> – The delivery of cell therapies via cellular cardiomyoplasty (ie, direct injection or implantation of cells into the myocardium) raises concerns for safety, though data are limited. Three concerns are ventricular arrhythmias (particularly after myoblast injection), myocardial ischemia, and undesired cell differentiation (eg, intramyocardial bone formation [<a href="#rid27">27</a>] or perivascular fibrosis [<a href="#rid28">28</a>]). There are conflicting data as to whether there is an increase in the risk of ischemia and acute coronary syndrome [<a href="#rid29">29,30</a>].</p><p></p><p class="headingAnchor" id="H464299276"><span class="h1">GENE THERAPY</span><span class="headingEndMark"> — </span>Gene therapy is under investigation for the treatment of HF [<a href="#rid31">31</a>], but published studies have not established the clinical value of this approach. Studies of gene therapy for HF are based upon advances in appropriate gene targets and in gene transfer technology, which include development of safe and efficient vectors and delivery methods [<a href="#rid32">32,33</a>]. Potential targets for gene therapy include cardiomyocyte calcium cycling (eg, through restoring activity of the sarcoplasmic reticulum calcium ATPase pump [SERCA2a] or improving S100A1 activity) and altering beta adrenergic system activity (eg, through inhibition of G-protein-couple receptor kinase 2 or improving adenylyl cyclase 6 activity).</p><p class="headingAnchor" id="H1700332"><span class="h1">NUTRITIONAL SUPPLEMENTS</span></p><p class="headingAnchor" id="H3786132403"><span class="h2">Hawthorn extract</span><span class="headingEndMark"> — </span>Hawthorn extract is an herbal agent derived from species of the hawthorn plant (<em>Crataegus monogyna</em> or <em>Crataegus laevigata</em>). Proposed mechanisms of action include vasodilation, as well as antioxidant activity, inotropy, and lipid effects [<a href="#rid34">34</a>].</p><p>The efficacy of hawthorn extract in the treatment of HF is uncertain; randomized trials have yielded mixed results. Although a meta-analysis found that hawthorn extract produced symptomatic and functional benefit in patients with chronic HF, two subsequently published randomized trials in patients with HF with reduced ejection fraction (HFrEF) found no benefit. It is unclear whether the difference in results is related to differences in patient populations (eg, the meta-analysis was not limited to HFrEF while the two later trials were limited to patients with HFrEF), differences in treatment regimens, or the effect of chance.</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis included 10 randomized trials enrolling a total of 855 patients with chronic HF (New York Heart Association [NYHA] class I to III); most of the trials did not require systolic dysfunction [<a href="#rid35">35</a>]. Treatment with hawthorn was associated with greater exercise tolerance and maximal achieved workload as well as reductions in pressure-heart rate product and symptoms of dyspnea and fatigue. Dosing varied widely (160 to 1800 mg), and the trials did not report data on mortality or HF hospitalization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two trials published after the meta-analysis found similar rates of death, hospitalization, and symptom improvement in the hawthorn and placebo groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The SPICE trial randomly assigned 2681 patients with NYHA class II to III HF and LVEF ≤35 percent to hawthorn extract or placebo. No effect of hawthorn was observed on the primary outcome of time until first cardiac event (cardiac death, nonfatal myocardial infarction, and hospitalization due to progressive HF) [<a href="#rid36">36</a>]. Adverse events were comparable in the two groups.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The HERB CHF trial randomly assigned 120 adults with NYHA class II to III chronic HF and LVEF ≤40 percent to hawthorn extract or placebo. There was no symptomatic or functional benefit from hawthorn extract compared with placebo at six-month follow-up [<a href="#rid37">37</a>]. Adverse events (most noncardiac) were significantly more frequent in the hawthorn group (60 versus 38 percent).</p><p></p><p class="headingAnchor" id="H157089775"><span class="h2">Coenzyme Q10</span><span class="headingEndMark"> — </span>Coenzyme Q10 is a vitamin-like, fat soluble quinone found in high concentrations in the mitochondria of the heart, liver, and kidney, where it is involved in electron and proton transfer during oxidative phosphorylation. It is also an antioxidant and free radical scavenger with membrane-stabilizing properties. Myocardial biopsies from patients with HF have demonstrated coenzyme Q10 depletion.</p><p>The role of coenzyme Q10 as a treatment for HF is unclear. The trials of coenzyme Q10 are small, subject to bias, and, in aggregate, suggest a wide range of efficacy that includes no effect:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis of randomized trials concluded that trials of coenzyme Q10 were subject to substantial bias and that there was an uncertain benefit of coenzyme Q10 when compared with placebo for the outcome of mortality (relative risk 0.68, 95% CI 0.45-1.03) and unclear or minimal effect on HF symptoms [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the randomized trials included in the meta-analysis provided evidence of clinical benefit from coenzyme Q10. In the Q-SYMBIO trial, 420 patients with chronic NYHA functional class III or IV HF were randomly assigned to either coenzyme Q10 100 mg three times daily or placebo, in addition to standard therapy [<a href="#rid39">39</a>]. Patients assigned to coenzyme Q10 had lower rates of cardiovascular mortality (9 versus 16 percent), all-cause mortality (10 versus 18 percent), and incidence of hospitalization for HF at two years. In addition, NYHA class improved in the coenzyme Q10 group. The rates of adverse events were similar in the two treatment groups (13 and 19 percent).</p><p></p><p class="headingAnchor" id="H690039829"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H7672953"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational therapies</strong> – The treatment of heart failure (HF) is designed to prolong survival, reduce morbidity, slow the progression of disease, and improve symptoms [<a href="#rid1">1</a>]. While the efficacy of many HF therapies has been established by conclusive trials, other plausibly effective therapies remain investigational due to inconclusive evidence.</p><p></p><p class="bulletIndent1">This topic reviews the following investigational therapies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parasympathetic simulation. (See <a class="local">'Parasympathetic stimulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enhanced external counterpulsation. (See <a class="local">'Enhanced external counterpulsation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac contractility modulation (CCM). (See <a class="local">'Cardiac contractility modulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stem cell therapies. (See <a class="local">'Stem cell therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gene therapy. (See <a class="local">'Gene therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional supplements including hawthorn extract and coenzyme Q10. (See <a class="local">'Hawthorn extract'</a> above and <a class="local">'Coenzyme Q10'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard therapies for heart failure</strong> – Standard therapies for HF with reduced ejection fraction and the management of HF with preserved ejection fraction are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:1810.</a></li><li><a class="nounderline abstract_t">Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008; 118:863.</a></li><li><a class="nounderline abstract_t">De Ferrari GM, Crijns HJ, Borggrefe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011; 32:847.</a></li><li class="breakAll">ANTHEM-HFrEF pivotal study. US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT03425422 (Accessed on June 07, 2022).</li><li class="breakAll">Low level tragus stimulation in acute decompensated heart failure (TREAT-HF). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT02898181 (Accessed on June 07, 2022).</li><li><a class="nounderline abstract_t">Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1198.</a></li><li><a class="nounderline abstract_t">Borggrefe M, Mann DL. Cardiac Contractility Modulation in 2018. Circulation 2018; 138:2738.</a></li><li><a class="nounderline abstract_t">Giallauria F, Vigorito C, Piepoli MF, Stewart Coats AJ. Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: an individual patient's data meta-analysis of randomized controlled trials. Int J Cardiol 2014; 175:352.</a></li><li><a class="nounderline abstract_t">Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail 2018; 6:874.</a></li><li class="breakAll">Cardiac contractility modulation therapy in amyloid cardiomyopathy patients with heart failure (AMY-CCM). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT05167799 (Accessed on June 07, 2022).</li><li class="breakAll">Observational and Prospective Registry on Cardiac Contractility Modulation (CCM) Therapy (REPORT-CCM). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04902079 (Accessed on June 07, 2022).</li><li class="breakAll">CCM Italian registry. US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04327323 (Accessed on June 07, 2022).</li><li class="breakAll">Assessment of CCM in HF with higher ejection fraction (AIM HIGHer). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT05064709 (Accessed on June 07, 2022).</li><li class="breakAll">Subanalysis in patients with CARDIoLAMinopathy enrolled to REPORT-CCM registry (CARDILAM-CCM). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04904393 (Accessed on June 07, 2022).</li><li class="breakAll">Post approval study (PAS) of the OPTIMIZER Smart and CCM therapy (PAS). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT03970343 (Accessed on June 07, 2022).</li><li><a class="nounderline abstract_t">Gyöngyösi M, Haller PM, Blake DJ, Martin Rendon E. Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction. Circ Res 2018; 123:301.</a></li><li><a class="nounderline abstract_t">Bolli R, Tang XL. Clinical trials of cell therapy for heart failure: recent results warrant continued research. Curr Opin Cardiol 2022; 37:193.</a></li><li><a class="nounderline abstract_t">Murry CE, Field LJ, Menasché P. Cell-based cardiac repair: reflections at the 10-year point. Circulation 2005; 112:3174.</a></li><li><a class="nounderline abstract_t">Murry CE. Cardiac aid to the injured but not the elderly? Nat Med 2007; 13:901.</a></li><li><a class="nounderline abstract_t">Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428:664.</a></li><li><a class="nounderline abstract_t">Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 2004; 10:494.</a></li><li><a class="nounderline abstract_t">Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 2002; 34:241.</a></li><li><a class="nounderline abstract_t">van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 2014; 509:337.</a></li><li><a class="nounderline abstract_t">Sultana N, Zhang L, Yan J, et al. Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun 2015; 6:8701.</a></li><li><a class="nounderline abstract_t">Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013; 113:810.</a></li><li><a class="nounderline abstract_t">Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2016; 12:CD007888.</a></li><li><a class="nounderline abstract_t">Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110:1362.</a></li><li><a class="nounderline abstract_t">Endo J, Sano M, Fujita J, et al. Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload. Circulation 2007; 116:1176.</a></li><li><a class="nounderline abstract_t">Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005; 46:1643.</a></li><li><a class="nounderline abstract_t">Zbinden S, Zbinden R, Meier P, et al. Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005; 46:1636.</a></li><li class="breakAll">Modulation of SERCA2a of intra-myocytic calcium trafficking in heart failure with reduced ejection fraction (MUSIC-HFrEF1). US National Library of Medicine. Available at: https://clinicaltrials.gov/ct2/show/NCT04703842 (Accessed on June 07, 2022).</li><li><a class="nounderline abstract_t">Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 2011; 57:1169.</a></li><li><a class="nounderline abstract_t">Pleger ST, Brinks H, Ritterhoff J, et al. Heart failure gene therapy: the path to clinical practice. Circ Res 2013; 113:792.</a></li><li><a class="nounderline abstract_t">Crataegus oxyacantha (Hawthorn). Monograph. Altern Med Rev 2010; 15:164.</a></li><li><a class="nounderline abstract_t">Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008; :CD005312.</a></li><li><a class="nounderline abstract_t">Holubarsch CJ, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008; 10:1255.</a></li><li><a class="nounderline abstract_t">Zick SM, Vautaw BM, Gillespie B, Aaronson KD. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J Heart Fail 2009; 11:990.</a></li><li><a class="nounderline abstract_t">Claxton L, Simmonds M, Beresford L, et al. Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. Health Technol Assess 2022; 26:1.</a></li><li><a class="nounderline abstract_t">Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014; 2:641.</a></li></ol></div><div id="topicVersionRevision">Topic 3478 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741057" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711023" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030409" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030409" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030409" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979005" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565990" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cardiac Contractility Modulation in 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975782" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: an individual patient's data meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754812" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976694" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35612934" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical trials of cell therapy for heart failure: recent results warrant continued research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286608" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cell-based cardiac repair: reflections at the 10-year point.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679999" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cardiac aid to the injured but not the elderly?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15107841" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11851363" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24805242" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : c-kit+ cells minimally contribute cardiomyocytes to the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515110" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Resident c-kit(+) cells in the heart are not cardiac stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989721" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28012165" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483296" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Potential risks of bone marrow cell transplantation into infarcted hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698734" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in response to pressure overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16256862" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16256861" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16256861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371634" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rescuing the failing heart by targeted gene transfer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989720" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Heart failure gene therapy: the path to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807002" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Crataegus oxyacantha (Hawthorn). Monograph.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254076" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hawthorn extract for treating chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19019730" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789403" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35076012" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282031" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
